Related Experiment Videos

TGF-beta1: a novel target for cardiovascular pharmacology

Santiago Redondo1, Carlos G Santos-Gallego, Teresa Tejerina

  • 1Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid Av Complutense s/n, Madrid, Spain.

Cytokine & Growth Factor Reviews
|May 9, 2007
PubMed

Insights

Transforming growth factor beta-1 (TGF-beta1) is crucial in cardiovascular disease. Research explores its potential as a biomarker and therapeutic target to restore protective functions and improve treatments.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Pharmacology

Background:

  • Transforming growth factor beta-1 (TGF-beta1) is integral to cardiovascular health.
  • Loss of TGF-beta1's protective functions contributes to cardiovascular disease progression.
  • The TGF-beta1 pathway influences the vascular effects of existing medications.

Purpose of the Study:

  • To review the role of TGF-beta1 in cardiovascular disease.
  • To evaluate TGF-beta1 as a potential disease marker.
  • To assess TGF-beta1 as a therapeutic target for cardiovascular conditions.

Main Methods:

  • Literature review of studies on TGF-beta1 and cardiovascular disease.
  • Analysis of the involvement of TGF-beta1 in current drug mechanisms.
  • Synthesis of evidence regarding TGF-beta1's utility as a biomarker and therapeutic target.

Main Results:

  • TGF-beta1's protective cardiovascular functions can be compromised.
  • Novel therapeutic strategies are emerging to restore TGF-beta1 function.
  • Existing drugs like aspirin, thiazolidinediones, and statins interact with the TGF-beta1 pathway.

Conclusions:

  • TGF-beta1 holds significant potential as a biomarker for cardiovascular disease.
  • Targeting TGF-beta1 offers a promising therapeutic avenue for cardiovascular conditions.
  • Further research is warranted to fully elucidate and leverage TGF-beta1's role in cardiovascular medicine.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...